Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free BIVIW Stock Alerts

BioVie (BIVIW) Financials

BioVie logo
$0.53 +0.03 (+5.80%)
As of 07/16/2026 02:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for BioVie

Annual Income Statements for BioVie

This table shows BioVie's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.23 -0.43 -1.33 -2.43 -2.49 -34 -184 -26 -50 -33 -18
Consolidated Net Income / (Loss)		 -0.23 -0.43 -1.33 -2.41 -2.44 -17 -130 -26 -50 -32 -18
Net Income / (Loss) Continuing Operations		 -0.23 -0.43 -1.33 -2.41 -2.44 -17 -130 -26 -50 -32 -18
Total Pre-Tax Income 		-0.23 -0.43 -1.33 -2.41 -2.44 -17 -130 -26 -50 -32 -18
Total Operating Income		 -0.23 -0.43 -1.55 -2.37 -2.50 -2.69 -138 -27 -45 -32 -18
Total Gross Profit		 -0.16 -0.18 -0.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.16 0.18 0.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 0.07 0.25 1.27 2.37 2.50 2.69 138 27 45 32 18
Selling, General & Admin Expense		 0.07 0.16 0.57 1.77 1.26 1.31 4.64 9.77 12 8.85 8.57
Research & Development Expense		 0.00 0.04 0.47 0.37 1.01 1.15 133 17 33 23 9.27
Amortization Expense		 0.00 0.05 0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.23
Total Other Income / (Expense), net		 0.00 0.00 0.22 -0.04 0.05 -14 7.80 1.17 -5.18 0.06 0.52
Interest Expense		 0.00 0.00 0.00 0.04 -0.05 4.77 0.50 2.16 4.30 2.89 0.33
Interest & Investment Income		 0.00 0.00 0.22 0.00 0.00 0.00 0.02 0.04 0.56 1.14 0.85
Other Income / (Expense), net		 - - - - 0.00 -9.21 8.28 3.29 -1.44 1.82 0.00
Preferred Stock Dividends Declared		 - - 0.00 0.02 0.05 17 54 - 0.00 0.89 0.37
Basic Earnings per Share		 $0.00 $0.00 ($0.01) ($0.03) ($0.98) ($6.85) ($14.82) ($1.06) ($15.47) ($73.05) ($12.12)
Weighted Average Basic Shares Outstanding		 87.21M 87.20M 89.39M 95.76M 2.54M 4.93M 12.40M 24.66M 3.25M 451.85K 1.48M
Diluted Earnings per Share		 $0.00 $0.00 ($0.01) ($0.03) ($0.98) ($6.85) ($14.82) ($1.06) ($15.47) ($73.05) ($12.12)
Weighted Average Diluted Shares Outstanding		 87.21M 87.20M 89.39M 95.76M 2.54M 4.93M 12.40M 24.66M 3.25M 451.85K 1.48M
Weighted Average Basic & Diluted Shares Outstanding		 87.21M 87.20M 89.39M 95.76M 317.45M 5.20M 24.83M 30.17M 36.80M 7.96M 7.53M

Quarterly Income Statements for BioVie

This table shows BioVie's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q3 2024 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 9/30/2024 3/31/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -11 -8.40 -8.95 -4.48 -8.95 -7.16 -2.79 -5.13 -6.07 -5.27
Consolidated Net Income / (Loss)		 -11 -8.40 -8.07 -4.15 -8.07 -7.11 -2.79 -5.09 -6.07 -5.27
Net Income / (Loss) Continuing Operations		 -11 -8.40 -8.07 -4.15 -8.07 -7.11 -2.79 -5.09 -6.07 -5.27
Total Pre-Tax Income 		-11 -8.40 -8.07 -4.15 -8.07 -7.11 -2.79 -5.09 -6.07 -5.27
Total Operating Income		 -11 -8.78 -7.73 -4.12 -7.73 -7.29 -2.99 -5.28 -6.26 -5.39
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 11 8.78 7.73 4.12 7.73 7.29 2.99 5.28 6.26 5.39
Selling, General & Admin Expense		 1.94 2.25 1.97 2.07 1.97 2.53 1.59 2.29 1.94 2.15
Research & Development Expense		 8.88 6.47 5.70 1.99 5.70 4.70 1.34 2.94 4.27 3.18
Amortization Expense		 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06
Total Other Income / (Expense), net		 0.17 0.38 -0.34 -0.03 -0.34 0.18 0.20 0.20 0.19 0.12
Interest Expense		 1.00 0.82 0.63 0.26 0.63 0.07 0.00 0.00 0.01 0.01
Interest & Investment Income		 0.46 0.22 0.18 0.22 0.18 0.25 0.20 0.20 0.20 0.12
Other Income / (Expense), net		 0.71 0.98 0.11 0.00 0.11 -0.01 0.01 0.00 0.00 0.00
Preferred Stock Dividends Declared		 0.00 0.00 0.89 0.33 0.89 0.04 0.00 0.04 0.00 0.00
Basic Earnings per Share		 ($2.92) ($2.20) ($0.20) ($7.00) ($2.00) ($4.55) ($1.51) ($0.98) ($0.77) ($0.70)
Weighted Average Basic Shares Outstanding		 3.67M 3.82M 44.80M 639.84K 4.48M 1.57M 1.85M 5.21M 7.92M 7.54M
Diluted Earnings per Share		 ($2.92) ($2.20) ($0.20) ($7.00) ($2.00) ($4.55) ($1.51) ($0.98) ($0.77) ($0.70)
Weighted Average Diluted Shares Outstanding		 3.67M 3.82M 44.80M 639.84K 4.48M 1.57M 1.85M 5.21M 7.92M 7.54M
Weighted Average Basic & Diluted Shares Outstanding		 37.74M 39.87M 61.02M 17.77M - 18.45M 18.56M 7.54M 7.54M 7.54M

Annual Cash Flow Statements for BioVie

This table details how cash moves in and out of BioVie's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 -0.07 -0.14 -0.12 0.04 0.29 -0.30 4.47 14 0.82 4.38 -6.30
Net Cash From Operating Activities		 -0.07 -0.15 -0.62 -0.62 -2.50 -1.63 -10 -19 -40 -28 -19
Net Cash From Continuing Operating Activities		 -0.06 -0.15 -0.64 -1.93 -2.03 -11 -10 -19 -40 -28 -19
Net Income / (Loss) Continuing Operations		 -0.23 -0.43 -1.33 -2.41 -2.44 -17 -130 -26 -50 -32 -18
Consolidated Net Income / (Loss)		 -0.23 -0.43 -1.33 -2.41 -2.44 -17 -130 -26 -50 -32 -18
Amortization Expense		 0.01 0.05 0.23 0.26 0.23 0.23 0.23 0.33 0.40 0.34 0.24
Non-Cash Adjustments To Reconcile Net Income		 0.00 0.01 0.09 0.89 0.17 14 120 4.01 9.83 3.88 0.51
Changes in Operating Assets and Liabilities, net		 0.16 0.22 0.39 0.64 -0.45 0.77 0.02 2.75 -0.23 -0.04 -2.23
Net Cash From Investing Activities		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 -14 15 0.00
Net Cash From Continuing Investing Activities		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 -14 15 0.00
Sale and/or Maturity of Investments		 - - - - - - - - - 15 0.00
Net Cash From Financing Activities		 0.00 -0.00 0.50 0.66 2.80 1.33 15 33 55 18 13
Net Cash From Continuing Financing Activities		 0.00 -0.00 0.50 0.66 2.80 1.33 15 33 55 18 13
Repayment of Debt		 - - 0.00 -0.04 -0.24 - - - 0.00 0.00 -5.85
Issuance of Common Equity		 - 0.00 0.48 0.45 - 0.00 16 19 55 28 16
Other Financing Activities, net		 - -0.00 0.00 - 0.00 1.26 -0.70 0.00 0.00 -10 2.90
Cash Interest Paid		 0.00 0.00 - 0.00 0.00 0.00 0.02 0.96 2.11 1.53 0.18

Quarterly Cash Flow Statements for BioVie

This table details how cash moves in and out of BioVie's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q1 2024 Q4 2024 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 9/30/2024 6/30/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 1.75 -0.99 -3.82 -6.51 -1.25 -5.61 7.43 -4.44 -7.44
Net Cash From Operating Activities		 -12 -5.91 -3.58 -4.01 -1.25 -5.61 -3.02 -4.44 -7.44
Net Cash From Continuing Operating Activities		 -12 -5.90 -3.58 -4.01 -1.25 -5.61 -3.02 -4.44 -7.44
Net Income / (Loss) Continuing Operations		 -11 -8.40 -4.15 -4.94 -2.79 -3.49 -5.09 -6.07 -5.27
Consolidated Net Income / (Loss)		 -11 -8.40 -4.15 -4.94 -2.79 -3.49 -5.09 -6.07 -5.27
Amortization Expense		 0.10 0.09 0.07 -0.70 0.06 0.06 0.06 0.06 0.06
Non-Cash Adjustments To Reconcile Net Income		 0.68 0.31 0.56 2.47 0.68 -1.42 2.46 0.40 -0.36
Changes in Operating Assets and Liabilities, net		 -2.26 2.11 -0.06 -0.84 0.80 -0.76 -0.46 1.18 -1.86
Cash Interest Paid		 0.53 0.43 0.14 0.23 0.00 0.00 0.00 0.01 0.01

Annual Balance Sheets for BioVie

This table presents BioVie's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets		 0.27 2.72 2.36 2.18 2.57 2.08 6.05 20 35 25 22
Total Current Assets		 0.27 0.13 0.01 0.05 0.67 0.41 4.61 19 34 24 21
Cash & Equivalents		 0.27 0.12 0.01 0.05 0.34 0.04 4.51 19 19 24 18
Prepaid Expenses		 0.00 0.01 - - - - 0.09 0.14 0.10 0.20 1.05
Other Current Assets		 - - - 0.00 0.33 0.38 - - - 0.00 2.10
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 2.59 4.72 2.13 1.90 1.67 1.44 1.33 1.06 1.16 0.86
Goodwill		 0.00 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35
Intangible Assets		 0.00 2.24 2.01 1.78 1.55 1.33 1.10 0.87 0.64 0.41 0.18
Other Noncurrent Operating Assets		 - - 2.36 - - - 0.00 0.12 0.08 0.41 0.34
Total Liabilities & Shareholders' Equity		 0.27 2.72 2.36 2.18 2.57 2.08 6.05 20 35 25 22
Total Liabilities		 0.32 0.80 1.21 2.06 0.44 24 1.00 16 20 9.70 2.55
Total Current Liabilities		 0.32 0.80 0.63 1.24 0.44 24 1.00 4.17 14 9.35 2.27
Accounts Payable		 0.00 0.30 0.51 0.88 0.44 1.26 1.00 2.44 3.48 3.59 2.20
Other Current Liabilities		 - - - - 0.00 22 0.00 1.73 1.91 0.06 0.07
Total Noncurrent Liabilities		 0.00 0.00 0.58 0.83 0.00 0.06 0.00 12 5.27 0.35 0.28
Other Noncurrent Operating Liabilities		 - 0.00 0.00 0.25 - - 0.00 0.14 0.04 0.35 0.28
Commitments & Contingencies		 - - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -0.05 1.92 1.16 0.11 2.13 -21 5.05 3.67 15 16 19
Total Preferred & Common Equity		 -0.05 1.92 1.16 0.11 2.13 -21 5.05 3.67 15 16 19
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -0.05 1.92 1.16 0.11 2.13 -21 5.05 3.67 15 16 19
Common Stock		 0.52 2.92 3.49 4.88 9.39 20 230 255 316 350 371
Retained Earnings		 -0.57 -1.00 -2.34 -4.77 -7.26 -41 -225 -251 -301 -334 -352
Treasury Stock		 - - - - - - - 0.00 -0.00 -0.00 -0.00

Quarterly Balance Sheets for BioVie

This table presents BioVie's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Total Assets		 24 21 32 21 26 25 27 23 18
Total Current Assets		 23 21 31 20 25 24 26 22 17
Cash & Equivalents		 21 20 30 20 24 23 25 21 13
Prepaid Expenses		 1.55 0.33 0.19 0.13 0.28 0.57 0.87 1.06 1.61
Other Current Assets		 - - - - - - 0.18 0.20 2.17
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 1.00 0.93 1.23 1.09 1.01 0.94 0.79 0.71 0.63
Goodwill		 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35
Intangible Assets		 0.58 0.52 0.47 0.35 0.29 0.24 0.12 0.06 0.01
Other Noncurrent Operating Assets		 0.07 0.06 0.42 0.39 0.37 0.36 0.32 0.30 0.28
Total Liabilities & Shareholders' Equity		 24 21 32 21 26 25 27 23 18
Total Liabilities		 16 14 13 7.17 1.77 2.84 1.90 3.24 1.91
Total Current Liabilities		 13 14 12 6.84 1.46 2.55 1.64 3.01 1.69
Accounts Payable		 2.71 3.61 4.41 3.45 1.38 2.48 1.57 2.92 1.61
Other Current Liabilities		 1.16 0.18 0.08 0.06 0.07 0.07 0.08 0.08 0.08
Total Noncurrent Liabilities		 3.00 0.02 0.37 0.33 0.31 0.30 0.25 0.23 0.21
Other Noncurrent Operating Liabilities		 0.03 0.02 0.37 0.33 0.31 0.30 0.25 0.23 0.21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 7.55 7.49 19 14 24 22 25 19 16
Total Preferred & Common Equity		 7.55 7.49 19 14 24 22 25 19 16
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 7.55 7.49 19 14 24 22 25 19 16
Common Stock		 319 328 348 353 370 370 382 383 384
Retained Earnings		 -312 -320 -329 -339 -346 -349 -357 -363 -369
Treasury Stock		 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00

Annual Metrics And Ratios for BioVie

This table displays calculated financial ratios and metrics derived from BioVie's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
DEI Shares Outstanding		 87,210,000.00 87,160,001.00 91,925,000.00 5,319,173.00 316,453,673.00 5,199,346.00 13,958,516.00 24,984,083.00 36,280,541.00 61,018,606.00 18,562,376.00
DEI Adjusted Shares Outstanding		 872,100.00 871,600.00 919,250.00 53,192.00 3,164,537.00 51,993.00 139,585.00 249,841.00 362,805.00 610,186.00 1,856,238.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.27 -0.50 -1.45 -45.76 -0.79 -649.62 -1,317.10 -104.40 -138.52 -54.09 -9.65
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 64.80% -68.40% -247.58% -59.81% -7.13% -414.96% -1,009.57% 81.75% -95.11% 34.90% 40.65%
EBIT Growth		 63.77% -84.83% -259.61% -52.69% -5.24% -376.84% -990.12% 81.53% -94.10% 34.73% 40.51%
NOPAT Growth		 63.77% -84.83% -259.61% -52.69% -5.24% -7.86% -5,026.62% 80.26% -65.41% 28.62% 43.86%
Net Income Growth		 27.61% -85.37% -208.08% -81.35% -1.29% -582.28% -681.02% 79.97% -92.67% 36.09% 45.39%
EPS Growth		 0.00% 0.00% 0.00% -200.00% -3,166.67% -598.98% -116.35% 92.85% -92.67% 36.09% 45.39%
Operating Cash Flow Growth		 62.17% -134.97% -305.92% 0.36% -302.61% 34.91% -541.99% -81.68% -111.96% 30.58% 31.92%
Free Cash Flow Firm Growth		 98.85% -68,989.60% -39.99% 152.78% -262.28% 837.91% -654.98% 86.76% -91.79% 19.81% 30.66%
Invested Capital Growth		 -99.16% 657.27% 128.06% -84.31% 179.27% -1,298.97% 102.51% -625.75% -50.63% 38.20% 155.66%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 4.49% -13.15% 0.00% 0.00% -309.13% -342.18% 84.04% -81.17% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% -8.31% -11.50% 0.00% 0.00% -322.37% -339.52% 83.85% -80.16% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% -8.31% -11.50% 0.00% 0.00% 32.00% -1,032.60% 82.13% -30.26% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 16.62% -966.01% 0.00% 0.00% -1,015.53% -323.64% 82.82% -85.49% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -60.05% -302.72% 87.10% -85.49% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 2.00% -239.21% -0.93% -15.66% -20.32% 14.30% -174.74% 5.68% -35.06% 20.67% -9.19%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -18.36% 0.00% 0.00% 0.00% -979.23% 85.27% -44.87% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 503.00% 184.25% 0.00% 0.00% -814.47% 375.33% 0.00% -24.32% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.84% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.84% 99.98% 85.65% 101.73% 97.91% 140.09% 100.37% 108.84% 108.04% 105.79% 97.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -397.39% -46.40% -86.60% -380.46% -218.03% 172.21% 1,583.74% -598.18% -528.70% -208.26% -101.64%
Cash Return on Invested Capital (CROIC)		 0.00% -134.82% -115.06% 75.51% -238.23% 0.00% -22,026.33% 0.00% 0.00% 0.00% -1,141.46%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -397.39% -46.40% -86.60% -380.46% -218.03% 172.21% 1,583.74% -598.18% -528.70% -208.26% -101.64%
Return on Equity Simple (ROE_SIMPLE)		 430.55% -22.54% -114.98% -2,170.09% -114.71% 77.57% -2,579.03% -710.57% -327.61% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.16 -0.30 -1.09 -1.66 -1.75 -1.89 -97 -19 -32 -23 -13
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -23.12% -66.20% 17.33% 43.50% 732.60% -9,402.99% -1,498.39% -127.24% -143.24% -50.84% -27.44%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - -106.22% -66.52%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -0.23 -0.43 -1.55 -2.37 -2.50 -12 -130 -24 -47 -30 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.23 -0.38 -1.32 -2.12 -2.27 -12 -130 -24 -46 -30 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 32.82 15.59 0.00 46.85 9.87 10.19 1.58 0.90
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 144.10 0.00 65.56 14.73 10.89 1.66 0.93
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 6.52 18.36 0.00 430.85 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 2.34 0.00 0.97 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.50 5.18 0.00 0.00 0.00 3.31 0.93 0.37 0.00
Long-Term Debt to Equity		 0.00 0.00 0.50 5.18 0.00 0.00 0.00 3.31 0.34 0.00 0.00
Financial Leverage		 -5.12 -0.21 0.91 2.73 0.08 0.02 0.27 -1.26 -1.37 -1.22 -1.03
Leverage Ratio		 5.14 1.61 1.65 3.58 2.12 -0.24 -0.49 3.00 2.90 1.96 1.36
Compound Leverage Factor		 5.13 1.60 1.42 3.64 2.07 -0.34 -0.50 3.26 3.14 2.07 1.32
Debt to Total Capital		 0.00% 0.00% 33.23% 83.82% 0.00% -0.29% 0.00% 76.78% 48.30% 26.88% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 30.69% 26.88% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 33.23% 83.82% 0.00% -0.29% 0.00% 76.78% 17.62% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 66.77% 16.18% 100.00% 100.29% 100.00% 23.22% 51.70% 73.12% 100.00%
Debt to EBITDA		 0.00 0.00 -0.43 -0.27 0.00 -0.01 0.00 -0.51 -0.31 -0.19 0.00
Net Debt to EBITDA		 0.00 0.00 -0.43 -0.25 0.00 0.00 0.00 0.28 0.43 0.60 0.00
Long-Term Debt to EBITDA		 0.00 0.00 -0.43 -0.27 0.00 -0.01 0.00 -0.51 -0.11 0.00 0.00
Debt to NOPAT		 0.00 0.00 -0.53 -0.35 0.00 -0.03 0.00 -0.64 -0.45 -0.25 0.00
Net Debt to NOPAT		 0.00 0.00 -0.52 -0.32 0.00 -0.01 0.00 0.34 0.62 0.81 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.53 -0.35 0.00 -0.03 0.00 -0.64 -0.17 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -6.26 37.91 -59.20 20.30 -19.21 -10.97 -20.33 -20.56
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.83 0.16 0.01 0.04 1.52 0.02 4.62 4.50 2.35 2.57 9.10
Quick Ratio		 0.83 0.15 0.01 0.04 0.77 0.00 4.53 4.47 2.34 2.55 7.71
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.00 -2.42 -3.38 1.79 -2.90 21 -119 -16 -30 -24 -17
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -29,829.65 0.00 43.59 0.00 4.48 -238.75 -7.26 -7.01 -8.35 -50.34
Operating Cash Flow to Interest Expense		 0.00 -1,896.68 0.00 -15.17 0.00 -0.34 -21.03 -8.78 -9.36 -9.66 -57.18
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -1,896.68 0.00 -15.17 0.00 -0.34 -21.03 -8.78 -9.36 -9.66 -57.18
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 1.21 0.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 300.92 517.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.32 1.79 4.09 0.64 1.79 -21 0.54 -2.83 -4.27 -2.64 1.47
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.16 2.11 2.29 -3.45 1.15 -23 22 -3.37 -1.43 1.63 4.10
Enterprise Value (EV)		 0.00 0.00 0.00 4.18 33 21 232 30 137 6.30 -0.37
Market Capitalization		 0.00 0.00 0.00 3.65 33 21 237 36 156 24 17
Book Value per Share		 $0.00 $0.02 $0.01 $0.00 $0.01 ($4.13) $0.36 $0.15 $0.42 $0.25 $1.02
Tangible Book Value per Share		 $0.00 ($0.01) ($0.01) ($0.02) $0.00 ($4.46) $0.26 $0.10 $0.40 $0.24 $1.00
Total Capital		 -0.05 1.92 1.73 0.69 2.13 -21 5.05 16 30 21 19
Total Debt		 0.00 0.00 0.58 0.58 0.00 0.06 0.00 12 14 5.70 0.00
Total Long-Term Debt		 0.00 0.00 0.58 0.58 0.00 0.06 0.00 12 5.23 0.00 0.00
Net Debt		 -0.27 -0.12 0.57 0.53 -0.34 0.03 -4.51 -6.50 -20 -18 -18
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.32 -0.80 -0.63 -1.24 -0.11 -23 -0.90 -4.03 -5.29 -3.45 0.88
Debt-free Net Working Capital (DFNWC)		 -0.05 -0.67 -0.63 -1.19 0.23 -23 3.61 15 29 20 18
Net Working Capital (NWC)		 -0.05 -0.67 -0.63 -1.19 0.23 -23 3.61 15 20 15 18
Net Nonoperating Expense (NNE)		 0.07 0.13 0.24 0.75 0.70 15 34 7.01 19 9.59 4.90
Net Nonoperating Obligations (NNO)		 -0.27 -0.12 2.93 0.53 -0.34 0.03 -4.51 -6.50 -20 -18 -18
Total Depreciation and Amortization (D&A)		 0.01 0.05 0.23 0.26 0.23 0.23 0.23 0.33 0.40 0.34 0.24
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.10) ($0.30) ($0.10) $0.00 ($148.20) ($10.60) ($15.50) ($73.00) ($12.12)
Adjusted Weighted Average Basic Shares Outstanding		 8.72M 8.72M 9.19M 9.58M 64.79M 0.00 1.24M 2.47M 3.25M 451.85K 1.48M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.10) ($0.30) ($0.10) $0.00 ($148.20) ($10.60) ($15.50) ($73.00) ($12.12)
Adjusted Weighted Average Diluted Shares Outstanding		 8.72M 8.72M 9.19M 9.58M 64.79M 0.00 1.24M 2.47M 3.25M 451.85K 1.48M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($0.10) ($0.30) ($0.10) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 8.72M 8.72M 8.94M 9.58M 31.75M 0.00 2.48M 3.02M 3.68M 795.67K 7.53M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.16 -0.30 -1.09 -1.66 -1.75 -1.89 -97 -19 -32 -23 -13
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -5,333.68 0.00 -57.91 0.00 -2.49 -261.14 -11.08 -10.82 -10.49 -54.29
NOPAT to Interest Expense		 0.00 -3,733.58 0.00 -40.54 0.00 -0.40 -194.46 -8.82 -7.34 -7.78 -38.01
EBIT Less CapEx to Interest Expense		 0.00 -5,333.68 0.00 -57.91 0.00 -2.49 -261.14 -11.08 -10.82 -10.49 -54.29
NOPAT Less CapEx to Interest Expense		 0.00 -3,733.58 0.00 -40.54 0.00 -0.40 -194.46 -8.82 -7.34 -7.78 -38.01
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for BioVie

This table displays calculated financial ratios and metrics derived from BioVie's official financial filings.

Metric Q1 2023 Q2 2023 Q1 2024 Q3 2024 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 9/30/2024 3/31/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 36,803,768.00 37,742,695.00 7,956,660.00 39,871,098.00 17,768,174.00 18,451,981.00 7,534,225.00 - 7,543,571.00
DEI Adjusted Shares Outstanding		 368,038.00 377,427.00 795,666.00 398,711.00 1,776,817.00 1,845,198.00 7,534,225.00 - 7,543,571.00
DEI Earnings Per Adjusted Shares Outstanding		 -29.58 -22.26 -5.63 -22.46 -4.03 -1.51 -0.68 - -0.70
Growth Metrics		 - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -8.30% 47.25% 59.77% 46.05% 0.00% 61.36% 0.00% 14.31% -82.24%
EBIT Growth		 -8.16% 47.01% 59.49% 46.09% 0.00% 60.90% 0.00% 14.20% -80.66%
NOPAT Growth		 -23.11% 23.61% 62.10% 43.87% 0.00% 61.35% 0.00% 14.13% -80.22%
Net Income Growth		 -2.83% 46.44% 61.23% 46.36% 0.00% 65.44% 0.00% 14.67% -89.01%
EPS Growth		 -2.83% 46.44% 61.23% 46.36% 0.00% 65.44% 0.00% 83.08% 53.64%
Operating Cash Flow Growth		 -32.07% 26.21% 70.60% 0.00% 0.00% 0.00% 0.00% 0.00% -493.67%
Free Cash Flow Firm Growth		 -304.23% -2,640.82% 81.73% -42.40% 0.00% 91.43% 0.00% 0.00% -904.71%
Invested Capital Growth		 46.62% 60.43% -94.08% 0.00% 0.00% 0.00% 0.00% -164.12% 288.04%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -257.70% 23.45% 80.51% 0.00% 0.00% 59.63% 0.00% -18.70% 14.13%
EBIT Q/Q Growth		 -261.72% 23.30% 80.32% 0.00% 0.00% 59.16% 0.00% -18.50% 14.00%
NOPAT Q/Q Growth		 -547.92% 19.26% 76.70% 0.00% 0.00% 59.03% 0.00% -18.50% 14.00%
Net Income Q/Q Growth		 -251.73% 21.56% 82.01% 0.00% 0.00% 60.80% 0.00% -19.30% 13.17%
EPS Q/Q Growth		 -251.73% 21.56% 82.01% 0.00% 0.00% 60.80% 0.00% 21.43% 9.09%
Operating Cash Flow Q/Q Growth		 -107.62% 51.47% 78.06% 0.00% 0.00% 0.00% 46.07% -46.76% -67.69%
Free Cash Flow Firm Q/Q Growth		 -500.74% -13.94% 85.32% 0.00% 0.00% 0.00% 0.00% 0.00% -111.99%
Invested Capital Q/Q Growth		 52.04% -87.01% 38.21% 0.00% 0.00% -176.24% 0.00% -2,126.17% 296.67%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 105.33% 107.73% 100.79% 105.83% 97.45% 93.54% 96.27% 96.92% 97.86%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -390.55% -113.79% -404.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -390.55% -113.79% -404.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -349.49% -254.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.61 -6.15 -2.89 -5.41 -5.10 -2.09 -3.70 -4.38 -3.77
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -35.58% -10.60% -9.89% 0.00% -8.23% -6.02% -5.56% -7.50% -8.28%
Return On Investment Capital (ROIC_SIMPLE)		 - -34.76% -16.60% - -21.34% -9.59% -14.84% -22.75% -24.15%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -10 -7.80 -4.12 -7.62 -7.30 -2.98 -5.28 -6.26 -5.39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -10 -7.71 -4.05 -7.57 -7.24 -2.92 -5.23 -6.20 -5.33
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 16.63 6.35 0.68 0.00 1.49 0.83 0.57 0.45 0.68
Price to Tangible Book Value (P/TBV)		 18.95 7.18 0.71 0.00 1.53 0.85 0.59 0.46 0.69
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 1.63 1.36 0.24 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.29 -1.27 -1.18 0.00 -1.02 -1.06 -1.00 -1.04 -0.97
Leverage Ratio		 3.45 2.05 2.08 0.00 1.07 1.13 1.08 1.12 1.13
Compound Leverage Factor		 3.64 2.20 2.10 0.00 1.05 1.06 1.04 1.08 1.10
Debt to Total Capital		 61.99% 57.64% 19.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 47.03% 57.64% 19.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 14.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 38.01% 42.36% 80.90% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.50 -0.58 -0.08 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.36 0.57 0.42 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.60 -0.55 -0.12 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.43 0.54 0.62 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -14.67 -19.66 -21.42 0.00 0.00 0.00 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 1.72 1.47 2.95 0.00 16.94 9.32 15.83 7.25 9.97
Quick Ratio		 1.61 1.45 2.93 0.00 16.75 9.09 15.19 6.83 7.73
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.80 -10 -1.61 -8.84 0.00 -0.76 0.00 -3.59 -7.61
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -8.76 -12.22 -6.28 -14.07 0.00 -151.60 0.00 -601.81 -1,275.76
Operating Cash Flow to Interest Expense		 -12.12 -7.20 -13.98 0.00 0.00 -250.80 -1,520.30 -743.71 -1,247.13
Operating Cash Flow Less CapEx to Interest Expense		 -12.12 -7.20 -13.98 0.00 0.00 -250.80 -1,520.30 -743.71 -1,247.13
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -1.36 -2.54 -2.64 0.00 -0.48 -1.33 -0.06 -1.28 2.51
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.19 3.88 -1.28 3.43 0.00 -1.33 0.00 -0.79 3.84
Enterprise Value (EV)		 117 38 -7.16 0.00 11 -5.07 -11 -12 -2.54
Market Capitalization		 126 48 9.55 21 36 18 14 8.75 11
Book Value per Share		 $0.21 $0.20 $0.23 $0.00 $1.35 $1.18 $3.31 $2.55 $2.07
Tangible Book Value per Share		 $0.18 $0.18 $0.22 $0.00 $1.31 $1.15 $3.25 $2.50 $2.02
Total Capital		 20 18 17 0.00 24 22 25 19 16
Total Debt		 12 10 3.32 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 2.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -8.91 -10 -17 0.00 -24 -23 -25 -21 -13
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.32 -3.45 -3.39 0.00 -1.18 -1.98 -0.59 -1.75 2.09
Debt-free Net Working Capital (DFNWC)		 19 17 17 0.00 23 21 24 19 15
Net Working Capital (NWC)		 9.55 6.58 13 0.00 23 21 24 19 15
Net Nonoperating Expense (NNE)		 3.10 2.25 1.27 2.66 2.01 0.70 1.39 1.69 1.50
Net Nonoperating Obligations (NNO)		 -8.91 -10 -17 0.00 -24 -23 -25 -21 -13
Total Depreciation and Amortization (D&A)		 0.10 0.09 0.07 0.06 0.06 0.06 0.06 0.06 0.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.90) ($2.20) ($7.00) $0.00 ($4.60) ($1.50) ($0.98) ($0.77) ($0.70)
Adjusted Weighted Average Basic Shares Outstanding		 3.67M 3.82M 639.84K 0.00 1.57M 1.85M 5.21M 7.92M 7.54M
Adjusted Diluted Earnings per Share		 ($2.90) ($2.20) ($7.00) $0.00 ($4.60) ($1.50) ($0.98) ($0.77) ($0.70)
Adjusted Weighted Average Diluted Shares Outstanding		 3.67M 3.82M 639.84K 0.00 1.57M 1.85M 5.21M 7.92M 7.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.77M 3.99M 1.78M 0.00 1.85M 1.86M 7.54M 7.54M 7.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.61 -6.15 -2.89 -5.41 -5.10 -2.09 -3.70 -4.38 -3.77
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 -10.12 -9.50 -16.09 -12.12 -109.43 -596.42 -2,656.91 -1,049.49 -902.53
NOPAT to Interest Expense		 -7.58 -7.49 -11.27 -8.61 -76.54 -418.52 -1,859.84 -734.64 -631.77
EBIT Less CapEx to Interest Expense		 -10.12 -9.50 -16.09 0.00 0.00 -596.42 -2,656.91 -1,049.49 -902.53
NOPAT Less CapEx to Interest Expense		 -7.58 -7.49 -11.27 0.00 0.00 -418.52 -1,859.84 -734.64 -631.77
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

BioVie Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioVie's financial year ends in June. Their financial year 2025 ended on June 30, 2025.

BioVie's net income appears to be on an upward trend, with a most recent value of -$17.54 million in 2025, rising from -$233.01 thousand in 2015. The previous period was -$32.12 million in 2024.

BioVie's total operating income in 2025 was -$18.07 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $18.07 million

Over the last 10 years, BioVie's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

BioVie's total liabilities were at $2.55 million at the end of 2025, a 73.7% decrease from 2024, and a 688.1% increase since 2015.

In the past 10 years, BioVie's cash and equivalents has ranged from $5.14 thousand in 2017 to $23.84 million in 2024, and is currently $17.54 million as of their latest financial filing in 2025.

Over the last 10 years, BioVie's book value per share changed from 0.00 in 2015 to 1.02 in 2025, a change of -170,800.0%.


Related Companies

Financial statements for NASDAQ:BIVIW last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel